COSMETIC COMPOSITIONS CONTAINING A SENNOSIDE

Abstract

COSMETIC COMPOSITIONS COMPRISING A SENNOSIDE The present invention relates to cosmetic compositions comprising a compound of formula (I) as described below, and their use to promote and / or accelerate skin regeneration, to prevent and / or treat signs of aging, and to promote and / or accelerate wound healing. The invention also relates to cosmetic processes comprising the application of such compositions. Figure for the abstract: none

Description

Title of the invention: COSMETIC COMPOSITIONS COMPRISING A SENNOSIDE

[0001] The present invention relates to cosmetic compositions comprising a compound of formula (I) as described below, or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof, or a salt thereof, in particular a mineral or organic salt thereof or a solvated form thereof, such as a hydrate thereof, and their use to promote and / or accelerate skin regeneration, to prevent and / or treat signs of aging, and to promote and / or accelerate wound healing. The invention also relates to cosmetic processes comprising the application of such compositions.

[0002] Human skin consists of two compartments: a deep compartment, the dermis, and a superficial compartment, the epidermis. The epidermis is in contact with the external environment and its role is to protect the body from dehydration and external chemical or mechanical aggressions.

[0003] Accelerated wound closure is an area of ​​intensive scientific research aimed at improving healing following a skin injury or in skin whose barrier function is compromised. For example, the skin barrier can be disrupted after a cosmetic procedure such as laser treatments and chemical peels, or in the presence of external aggressions, such as irritants (detergents, acids, bases, oxidizers, reducing agents, concentrated solvents, toxic gases or fumes), mechanical stresses (friction, shocks, abrasion, surface tearing, projection of dust, particles, shaving or waxing), thermal or climatic imbalances (cold, dryness, radiation), xenobiotics (undesirable microorganisms, allergens) or internal attacks such as psychological stress.Following such external aggressions, a healing process is triggered, aiming to rapidly and completely restore this barrier. This physiological process depends on complex biological mechanisms involving numerous molecules and enzymes.

[0004] There is a need for compositions that promote skin healing and, in particular, that accelerate skin healing.

[0005] The objective of the invention is therefore to propose a cosmetic composition that meets all these requirements.

[0006] The inventors have discovered in an astonishing way that natural molecules of formula (I) are capable of accelerating wound healing and are therefore potentially useful for skin regeneration.

[0007] This application proposes compositions to accelerate skin regeneration following a skin injury or a cosmetic procedure, to promote healing following said skin injury, and / or to improve the effectiveness of cosmetic skin procedures. The use of these compositions will result in faster healing and recovery time following the procedure, leading to a greater willingness on the part of the patient to undergo cosmetic procedures.

[0008] Thus, the present invention relates to a cosmetic composition comprising, in a cosmetically acceptable medium: • at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof, or a solvate thereof such as a hydrate thereof, and • at least one compound selected from among thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light protection agents also known as UV filters, polymers, hydrophilic and lipophilic gelling agents.

[0009] For the purposes of the present invention, and unless otherwise indicated: • an “alkyl” radical is a saturated hydrocarbon radical, linear or branched, in particular Ci-C6, preferably Ci-C4; • a “(poly)(hydroxy)(Ci-C6)alkyl radical” means an alkyl radical in Ci-C6, preferably an alkyl radical in Ci-C4, optionally substituted by one or more hydroxy radicals, preferably substituted by 1 to 4 hydroxy groups, more particularly by 1 to 3 hydroxy groups; • A "sugar" radical is a monosaccharide or a disaccharide radical. Examples of sugar radicals are sucrose, glucose, galactose, ribose, fucose, maltose, fructose, mannose, arabinose, xylose or lactose; • a “monosaccharide” means a monosidic sugar comprising at least 5 carbon atoms of formula CX(H2O)X, x being an integer greater than or equal to 5, preferably x is greater than or equal to 6, in particular x is from 5 to 7, preferably x = 6; They may be of D or L configuration, and of alpha or beta anomer, as well as one of its salts or one of its solvates such as hydrates; • “Disaccharide” refers to a disaccharide sugar, which is a compound made up of of two sugars linked together by O-glycosidic bonds, said compounds consisting of two monosaccharides (also called mono-osidics) as defined above, said monosaccharide motifs comprising at least 5 carbon atoms, preferably 6, in particular the monosaccharide motifs are linked together in 1,4 or 1,6, of alpha or beta anomer, each glycosidic motif being of L or D configuration, as well as one of its salts or solvates such as hydrates. A disaccharide is more particularly a polymer formed from two sugars (or monosaccharides) corresponding to the general formula: [Cx(H2O)y)]2 or [(CH2O)x]2, x being an integer greater than or equal to 5, preferably x is greater than or equal to 6, in particular x is from 5 to 7, preferably x = 6, and y is an integer that represents x-1; • By “mineral or organic salt”, we mean the salt of bases or alkaline agents, such as alkali metal hydroxides such as soda, potash, ammonia, amines, alkanolamines, or salts of so-called “basic” amino acids such as lysine or arginine.

[0010] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, to promote and / or accelerate skin regeneration.

[0011] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, to prevent and / or treat signs of aging.

[0012] Another object of the invention is the use of said compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvate thereof, or a composition according to the invention, to promote and / or accelerate wound healing.

[0013] The present invention also relates to a non-therapeutic method for treating the skin comprising the step of applying said at least one compound or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof, or a salt thereof, or a solvate thereof, or the composition according to the invention, to the skin.

[0014] Another object of the invention is a skin treatment method to promote and / or accelerate wound healing after cosmetic procedures, the method comprising: a. Skin treatment with at least one skin-modifying stimulus, and b. after step (a) the application of a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer of this (such as an alpha or beta anomer), or a tautomer of it or a salt of it, or a solvate of it, on the skin.

[0015] Other subjects, features, aspects and advantages of the invention will become even clearer upon reading the description and examples that follow.

[0016] Compositions

[0017] The composition according to the invention comprises at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof: Formula (I)

[0018] in which: • R' and R" are identical or different, preferably identical, and represent H or a monosaccharide or a polysaccharide comprising up to 20 sugar motifs, preferably up to 6 sugar motifs, in the form of pyranose and / or furanose and of range L and / or D, said mono- or polysaccharide may be substituted by a hydroxyl group which is obligatorily free, and optionally one or more amine functions, optionally one or more protected amine functions, and said monosaccharide or polysaccharide being optionally substituted on its CH2OH group by a -C(O)-CO2H group; • R represents H or -C-(O)-O-Ri or -Alk-X-Ri, preferably -C-(O)-OR i or Alk-O-Ri, X being O, S or -NR1, preferably O; Ri being H or a saturated or unsaturated hydrocarbon chain, preferably saturated in Ci-C6, more preferably Ri corresponds to H, and Alk corresponds to an alkylene group in Ci-C6> preferably -CH2-.

[0019] Advantageously, R' and R" are identical or different and represent a monosaccharide or polysaccharide containing up to 6 sugar units, in the form of pyranose and / or furanose and of range L and / or D, said mono- or polysaccharide having at least one obligatorily free hydroxyl function and / or optionally one or more obligatorily protected amine functions.

[0020] Advantageously, the monosaccharide is selected from D-glucose, D-galactose, D-mannose, D-xylose, D-lyxose, L-fucose, L-arabinose, L-rhamnose, D-glucuronic acid, D-galacturonic acid, D-iduronic acid, N-acetyl-D-glucosamine, and N-acetyl-D-galactosamine. Monosaccharide advantageously designates D-glucose, L-rhamnose, D-xylose, N-acetyl-D-glucosamine, or L-fucose, and more preferably D-glucose.

[0021] Advantageously, the polysaccharide containing up to 6 sugar motifs can be selected from D-maltose, D-lactose, D-cellobiose, D-maltotriose, a disaccharide combining a uronic acid selected from D-iduronic acid or D-glucuronic acid with a hexosamine selected from D-galactosamine, D-glucosamine, N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, a disaccharide combining L-rhamnose and D-galactose, an oligosaccharide containing at least one xylose which can advantageously be selected from xylobiose, methyl-[3-xylobioside, xylotriose, xylotetraose, xylopentaose and xylohexaose and particularly, xylobiose which is composed of two xylose molecules linked by a 1-4 bond.

[0022] More preferably, R' and R" are identical and represent a monosaccharide selected from D-glucose, D-xylose, L-fucose, L-rhamnose, D-galactose and D-maltose, preferably D-glucose.

[0023] The monosaccharide or polysaccharide of R' and / or R" can be substituted on one or more hydroxymethyl residues by a -C(O)-COOH group.

[0024] Advantageously, said compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvated thereof such as a hydrate thereof, is in the form of a plant extract.

[0025] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0026] The compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvated form thereof such as a hydrate thereof, preferably Sennoside A or one of its salts, is present in solubilized form in the composition. By "in solubilized form", we mean that the compound does not form crystals visible to the naked eye in the composition.

[0027] Sennoside A (C42H38O2O) (or (97?)-9-[(97?)-2-carboxy-4-hydroxy-10-oxo-5-[(25,3R,45,55,67?)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9 7 / -anthracene-9-yl]-4-hydroxy-10-oxo-5-[(25,37?,45,55,67?)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9 / / -anthracene-2-carboxylic acid in IUP name AC) has CAS number 81-27-6 and formula (I'). Formula (I')

[0028] Sennoside, and preferably sennoside A, may also be present in salt form.

[0029] By "salt" is meant a cosmetically acceptable salt, that is to say, a salt that is compatible with application to the skin, mucous membranes and / or appendages. The salt of the compound of formula (I), preferably the sennoside A salt, may be an alkali or alkaline earth metal salt, preferably a calcium, magnesium, sodium or potassium salt.

[0030] Typically, the salt of the compound of formula (I), preferably the sennoside salt such as sennoside salt A, may exist once the compound has been introduced into the composition. In fact, the compound of formula (I) is introduced into the composition in an unsalted form.

[0031] Preferably, the composition comprises a sennoside A, for example sennoside A marketed by INTERCHIM under the name Sennoside A.

[0032] Preferably, the composition comprises a mixture of sennosides containing at least sennoside A.

[0033] Preferably, the composition comprises between 0.01% and 5% by weight relative to the total weight of the composition, more preferably between 0.2% and 4%, even more preferably between 0.3% and 3%, or between 0.4% and 1% by weight relative to the total weight of the composition of the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof.

[0034] Preferably, the composition comprises between 0.1 and 5% by weight of sennoside A or one of its salts relative to the total weight of the composition, preferably between 0.2 and 4% by weight, more preferably between 0.3 and 3% by weight, most preferably between 0.4 and 1% by weight.

[0035] Unless otherwise stated, percentages are expressed as a percentage of the total weight of the composition.

[0036] Finally, the composition according to the invention includes ingredients commonly used in the cosmetic field.

[0037] The composition according to the invention comprises at least one compound selected from thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light-protecting agents also known as UV filters, polymers, and hydrophilic and lipophilic gelling agents. A person skilled in the art can adjust the type and quantity of these ingredients in the compositions according to the invention through routine operations, so that the desired cosmetic properties and the stability properties of these compositions are not negatively affected. The quantities of these various ingredients are conventionally those used in the particular field, for example, from 0.01% to 20% of the total weight of the composition.

[0038] In one embodiment, the composition of the invention further comprises one or more cutaneous active agents selected from anti-aging agents and wound healing agents.

[0039] The term "anti-aging agents" refers to all cosmetic agents known to a person skilled in the art suitable for reducing and / or slowing down the progression of signs of skin aging such as marked skin micro-relief, fine lines, the appearance of wrinkles, loss of tone, loss of density, loss of firmness, loss of elasticity, decrease in the thickness of the dermis and / or epidermis, dryness, withered skin, loss of radiance of complexion, the appearance of a dehydrated appearance of the skin, sagging of the skin, withering of the skin and loss of the skin's ability to regenerate.

[0040] The expression "wound healing agents" means any cosmetic agent known to a person skilled in the art suitable for promoting and / or accelerating wound healing.

[0041] One or more cutaneous active agents may be included in the cosmetic composition in an amount ranging from 0.001% to 5% by weight relative to the total weight of the composition, more preferably between 0.01% and 2%, even more preferably between 0.02% and 1%, or between 0.05% and 1% by weight relative to the total weight of the composition.

[0042] In another embodiment, the composition of the invention comprises only at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof, or a solvated form thereof such as a hydrate thereof, as a cutaneous active agent.

[0043] The composition according to the invention comprises a cosmetically acceptable medium.

[0044] Here, “cosmetically acceptable medium” means a non-toxic carrier that can be applied to keratinous materials such as skin and mucous membranes. Thus, a cosmetically acceptable medium is compatible with the skin, integument, and / or mucous membranes; it does not induce any sensation of discomfort, or more generally, any disturbance likely to cause the user to suspend or discontinue the administration of the cosmetic composition.

[0045] More specifically, said cosmetically acceptable medium may comprise water and / or one or more water-miscible organic solvents. Said solvent may be selected from polyols and alcohols, such as glycerin, sorbitol, glycols such as butylene glycol, propylene glycol, isoprene glycol, dipropylene glycol, hexylene glycol, polypropylene glycol, ethanol or propanediol.

[0046] Preferably, the composition according to the invention has a water content ranging from 20% to 95% by weight, more preferably from 30% to 70% by weight relative to the total weight of the composition.

[0047] A composition according to the invention may include an oily phase.

[0048] The compositions according to the invention can have all dosage forms conventionally used for topical application, particularly in the form of aqueous solutions, hydroalcoholic solutions, oil-in-water (O / W) or water-in-oil (W / O) emulsions, or multiple (triple: O / W or W / O / O) emulsions, aqueous gels, or dispersions of an oily phase in an aqueous phase using spheres, these spheres potentially being ionic and / or non-ionic lipid vesicles (liposomes, niosomes, oleosomes). These compositions are prepared using routine processes.

[0049] The cosmetic compositions of this disclosure are preferably stable. The term "stable" as used here means that the cosmetic composition does not visually separate the phases or crystallize and degrade completely.

[0050] In a preferred embodiment, the compositions used in the context of the invention are intended for topical administration. In a preferred embodiment, the compositions used in the context of the invention are intended to be applied to the skin.

[0051] In the context of the invention, the term "skin" means any cutaneous surface of the body, preferably the skin of the face or neck or legs, and more particularly the skin of the face or neck.

[0052] Advantageously, the compositions according to the invention are in the form of a gel, an emulsion, a powder, or a paste. Furthermore, the composition according to the invention may be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foaming gel, a scrub, a mask, a treatment, a toner, or a mousse.

[0053] The compositions according to the invention can be applied directly to the skin or, alternatively, to occlusive or non-occlusive cosmetic carriers intended for local application to the skin. Non-limiting examples of cosmetic carriers include a bandage, a wipe, or a mask on a support. The composition may or may not be rinsed off after application to the skin; preferably, it is not rinsed off.

[0054] Uses

[0055] The present invention also relates to the use of at least one compound of formula (I) as described herein or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, to promote and / or accelerate skin regeneration.

[0056] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0057] The present invention also relates to the use of a composition according to the invention, to promote and / or accelerate skin regeneration.

[0058] Skin regeneration is the innate ability of living organisms to repair their skin through a healing process. In the context of the invention, skin regeneration can follow a skin injury, or occur when the skin's barrier function is compromised, for example, during or after cosmetic surgery procedures.

[0059] Here, the term "promote" refers to increasing the effects of the phenomenon. For example, promoting skin regeneration can lead to greater skin generation than without the use according to the invention.

[0060] Here, the term "accelerate" refers to the acceleration of the phenomenon. For example, accelerating skin regeneration can result in the same amount of regenerated skin but in less time than without the use according to the invention.

[0061] The present invention relates to the use of at least one compound of formula (I) as described herein or of an optical isomer thereof, or of a cis-trans isomer thereof (such as an alpha or beta anomer), or of a tautomer thereof or of a salt thereof, in particular a mineral or organic salt thereof or of a solvate thereof such as a hydrate thereof, according to the invention, to prevent and / or treat the signs of aging.

[0062] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0063] The present invention relates to the use of the composition according to the invention, to prevent and / or treat the signs of aging.

[0064] Here, the term "prevent" or "prevention" refers to any action aimed at preventing the onset of discomfort or inconvenience in an individual. This term therefore covers the cessation or limitation of symptoms, but is limited to cosmetic aspects.

[0065] Here, the term "treat" or "treatment" refers to any action aimed at improving an individual's comfort or well-being. This term therefore covers the alleviation, slowing, reduction, or suppression of symptoms, but is limited to cosmetic treatment.

[0066] The expression "signs of aging" here refers to all the changes that occur in a subject with age. Preferably, the signs of aging according to the invention are signs of skin aging.

[0067] The expression "signs of skin aging" or "signs of skin aging" here refers to all the changes in the skin that occur with age and that are sometimes not visible at an early stage. Signs of skin aging include marked skin micro-relief, fine lines, the appearance of wrinkles, loss of tone, loss of density, loss of firmness, loss of elasticity, decreased thickness of the dermis and / or epidermis, dryness, withered skin, loss of radiance, the appearance of a dehydrated skin, sagging skin, skin wilting, and loss of the skin's ability to regenerate.

[0068] The present invention relates to the use of at least one compound of formula (I) as described herein or of an optical isomer thereof, or of a cis-trans isomer thereof (such as an alpha or beta anomer), or of a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, to promote and / or accelerate wound healing.

[0069] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0070] The present invention relates to the use of a composition according to the invention, to promote and / or accelerate the healing of wounds and in particular the healing of skin wounds.

[0071] Wound healing is the innate ability of living organisms to heal from a wound through a healing process. In the context of the invention, skin regeneration can follow a skin injury or a skin wound.

[0072] Preferably, the uses according to the invention are topical uses. Preferably, the composition is applied to the skin, more preferably to the face, legs or body, more preferably to the face.

[0073] Processes

[0074] The invention relates to a non-therapeutic, preferably cosmetic, skin treatment method comprising the step of applying the composition according to the invention to the skin.

[0075] Preferably, the application step of the composition is carried out by topical application of said composition, more preferably on the face, legs or body, more preferably on the face or neck.

[0076] Preferably, the skin shows at least one sign of skin aging as defined above.

[0077] Preferably, the application is carried out on the skin of a subject who needs it and in an effective quantity of the composition. Here, the term "subject" means a human being.

[0078] Preferably, the subject does not suffer from dermatological lesions and / or dermatological diseases, more preferably the subject does not suffer from any diseases.

[0079] Here, the expression "effective quantity" refers to the quantity of composition according to the invention, which, as a whole, makes it possible to: • promote and / or accelerate skin regeneration, and / or • prevent and / or treat the signs of aging, and / or • to promote and / or accelerate wound healing.

[0080] According to the present invention, the methods are non-therapeutic methods.

[0081] The methods of the invention may include a single administration. In another embodiment, the administration is repeated, for example, 2 to 3 times a day for one day or more and generally for a prolonged period of at least 4 weeks or 4 to 15 weeks, or as long as necessary.

[0082] The invention also relates to a non-therapeutic, preferably cosmetic, method for treating the skin to promote and / or accelerate wound healing after aesthetic procedures, the method comprising: a. Skin treatment with at least one skin-modifying stimulus, and b. after step (a) the application of a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvated thereof according to the invention on the skin.

[0083] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0084] In yet other embodiments, the non-therapeutic, preferably cosmetic, process according to the invention comprises: a. Skin treatment with at least one type of skin-modifying stimulus, for example, an exfoliating agent, laser, radiofrequency, electrical energy, heat, low-level light, needle, or abrasive instrument; and b. after step (a) the application of a composition comprising a compound of formula (I), or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, or a solvated thereof, according to the invention on the skin, in particular within approximately 6 hours after step (a).

[0085] Preferably, the compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof (such as an alpha or beta anomer), or a tautomer thereof or a salt thereof, in particular a mineral or organic salt thereof or a solvate thereof such as a hydrate thereof, is selected from sennosides A, B, C, D, E and F, preferably it is selected from sennosides A and B, even more preferably the compound of formula (I) is sennoside A or one of its salts.

[0086] By "skin-modifying stimulus" is meant an action on the skin that will induce a change in the skin, such a stimulus being able to temporarily compromise the skin's barrier function. For example, skin modification includes an exfoliating agent, a laser, radiofrequency, electrical energy, heat, low-level light, a needle, or an abrasive instrument.

[0087] The invention also relates to a non-therapeutic, preferably cosmetic, method for treating the skin to promote and / or accelerate wound healing after aesthetic procedures, the method comprising: a. Skin treatment with at least one skin-modifying stimulus, and b. after step (a) the application of a composition according to the invention to the skin.

[0088] In still other embodiments, the method according to the invention comprises: a. treating the skin with at least one type of skin-modifying stimulus, for example, an exfoliating agent, a laser, radiofrequency, electrical energy, heat, low-level light, a needle, or an abrasive instrument; and b. after step (a) the application of a composition according to the invention to the skin, in particular within approximately 6 hours after step (a). Brief description of the drawings

[0089] [Fig-1] [Fig.1]: Acceleration of wound closure in reconstructed skin 3D. Treatment of full-thickness reconstructed skin from day 10 after the start of reconstruction resulted in a statistically significant acceleration of wound closure by day 14, as determined by OCT. Data are represented as box plots. ** represents p<0.01, one-way ANOVA, n=6, representative of 3 independent experiments.

[0090] [Fig. 2] [Fig. 2]: Acceleration of wound closure in 3D reconstructed skin. Treatment of full-thickness reconstructed skin from day 10 after the start of reconstruction resulted in a statistically significant acceleration of wound closure by day 15, as determined by OCT. Data are represented as box plots. ** represents p<0.01, one-way ANOVA, n=6, representative of 3 independent experiments. Example#: Materials and Processes

[0091] Organotypic healing of 3D reconstructed skin wounds

[0092] Reconstructed T-skin models were constructed as previously described (Bataillon, et al., Characterization of a New Reconstructed Full Thickness Skin Model, T-SkinTM, and its Application for Investigations of Anti-Aging Compounds. Int J Mol Sci. 2019 May; 20(9)). In short, keratinocytes and fibroblasts were isolated from skin biopsies. A ring was placed on the surface of the epidermis that would prevent keratinocyte coverage of this area, providing an area of ​​exposed collagenized dermis and simulating a partial-thickness wound. On day 10, The ring was removed, and the wound was treated with either an indicated raw material or a 1 / 1000 DMSO control vehicle in PBS. The wound was treated every three days. Oncostatin (10 ng / mL) and vitamin C (100 pg / mL) were used as positive controls. The rate of wound closure was determined by optical coherence tomography (OCT) to monitor wound closure. The rate of closure is expressed as a percentage increase in closure compared to the control. Data are presented as box plots with three replicates per condition in Figures 1 and 2. Statistical analysis was performed using a one-way ANOVA with post-hoc analysis and Levene's test for homogeneity of variance. The data are representative of three independent experiments. RESULTS

[0093] The compound of formula (I) accelerates wound healing in an organotypic 3D reconstructed skin model

[0094] A wound healing model was used to determine the ability of sennoside A (50 pM) to accelerate wound closure over a 20-day period. The two positive controls, Oncostatin M (2 ng / mL) and Vitamin C (100 pg / mL), accelerated wound closure on days 14 (Fig. 1) and 15 (Fig. 2), as expected. Similarly, sennoside accelerated wound closure. These data demonstrate that sennoside can accelerate the healing and regeneration of skin wounds. CONCLUSION

[0095] These data demonstrate that a compound of formula (I) induces wound closure in a 3D reconstructed skin healing model. The invention therefore has clear indications for use in skin regeneration, wound healing, promoting skin healing following a surgical / cosmetic procedure, and associated skin health outcome indicators requiring skin cell modulation.

Claims

1. Demands Cosmetic composition, comprising in a cosmetically acceptable medium: - at least one compound of formula (I) or an optical isomer thereof, or a cis-trans isomer thereof, or a tautomer thereof or a salt thereof, or a solvate thereof, R'"- OO OH in which: - R' and R" are identical or different, preferably identical, and represent H or a monosaccharide or a polysaccharide comprising up to 20 sugar motifs, preferably up to 6 sugar motifs, in the form of pyranose and / or furanose and of range L and / or D, said mono- or polysaccharide may be substituted by a hydroxyl group which is obligatorily free, and optionally one or more amine functions, optionally one or more protected amine functions, and said monosaccharide or polysaccharide being optionally substituted on its CH2OH group by a -C(O)-CO2H group; - R represents H or -C-(O)-O-Ri or -Alk-X-Ri, preferably -C-(O)-O-Ri or Alk-O-Ri, X being O, S or -NR1, preferably O; Ri being H or a saturated or unsaturated hydrocarbon chain, preferably saturated in Ci-C6, more preferably Ri corresponds to H, and Alk corresponds to an alkylene group in Ci-C6> preferably -CH2-; And ; - at least one compound chosen from among thickeners, preservatives, perfumes, bactericides, pigments, dyes, carbon and / or silicone or inorganic oils, waxes, fillers, emulsifiers, co-emulsifiers, UVA and / or UVB light protection agents also known as UV filters, polymers, hydrophilic and lipophilic gelling agents.

2. Composition according to claim 1, wherein said compound is a sennoside.

3. Composition according to claim 2, wherein said sennoside is a sennoside A, B, C, D, E, F, an enantiomer thereof, or a cis-trans isomer thereof.

4. Composition according to any one of claims 1 to 3 further comprising one or more cutaneous active agents selected from anti-aging agents and wound-healing agents.

5. Composition according to any one of claims 1 to 4, characterized in that the concentration of said at least one compound of formula (I) is between 0.01% and 5% by weight relative to the total weight of the composition.

6. A compound of formula (I) according to claim 1, or of an optical isomer thereof, or of a cis-trans isomer thereof (such as an alpha or beta anomer), or of a tautomer thereof or of a salt thereof, or of a solvated thereof, for preventing and / or treating signs of aging.

7. Composition according to any one of claims 1 to 5, for preventing and / or treating signs of aging.

8. Compound according to claim 6, wherein the signs of aging are signs of skin aging.

9. Non-therapeutic method of skin treatment, comprising applying the composition according to any one of claims 1 to 5 to the skin.

10. A method according to claim 9, wherein the skin exhibits at least one sign of skin aging.

Images